What is Relay Therapeutics Inc (RLAY) stock price today?

Relay Therapeutics Inc (RLAY) currently trades at $12.57 per share. The stock has a market capitalization of $2.41B and a P/E ratio of —x.

Is RLAY stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Relay Therapeutics Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 2.21.

What is Relay Therapeutics Inc's revenue and earnings?

Relay Therapeutics Inc has trailing twelve-month (TTM) revenue of $15.36M with profit margins of 0.00%. Earnings per share (EPS) is $-1.61.

Is Relay Therapeutics Inc financially healthy?

Relay Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 2.21 places it in the grey zone.

RLAY

Relay Therapeutics Inc

NASDAQ: RLAY · HEALTHCARE · BIOTECHNOLOGY

$12.57

-3.53% today

Updated 2026-04-29

Market cap

$2.41B

P/E ratio

—

P/S ratio

156.64x

EPS (TTM)

$-1.61

Dividend yield

—

52W range

$3 – $17

Volume

3.0M

Market cap

$2.41B

P/E ratio

—

P/S ratio

156.64x

EPS (TTM)

$-1.61

Dividend yield

—

52W range

$3 – $17

Volume

3.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

8.0

Quality

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

2.2

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$21.00

+67.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.05x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-44.87M

- Revenue declining -23.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.38M	$25.55M	$10.01M	$15.36M	$15.36M
Net income	$-290.51M	$-341.97M	$-337.71M	$-276.48M	$-54.89M
EPS	—	—	—	—	$-1.61
Free cash flow	$-238.55M	$-304.44M	$-251.13M	$-235.87M	$-44.87M
Profit margin	-21,036.13%	-1,338.66%	-3,374.72%	-1,800.58%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RLAY	$2.41B	24	5.3	2.5	5.0	8.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Relay Therapeutics Inc trades at $12.57. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.21, it sits in the grey zone. TTM revenue stands at $15.36M.

Frequently asked questions

What is Relay Therapeutics Inc's stock price?

Relay Therapeutics Inc (RLAY) trades at $12.57.

Is Relay Therapeutics Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Relay Therapeutics Inc (RLAY)?

The analyst target price is $21.00, representing +67.1% upside from the current price of $12.57.

What is Relay Therapeutics Inc's revenue?

TTM revenue is $15.36M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

2.21 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.relaytx.com

Quick metrics

P/S ratio156.64x

ROE-41.10%

Beta1.58

50D MA$11.72

200D MA$7.53

Shares out0.19B

Float0.11B

Short ratio—

Avg volume3.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RLAY vs LLY →RLAY vs JNJ →RLAY vs ABBV →Stock screener →